Sunovion Pharmaceuticals Inc.
84 Waterford Drive
Marlborough
Massachusetts
01752
United States
Tel: 508-481-6700
Website: http://www.sunovion.com/
About Sunovion Pharmaceuticals Inc.
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people living with serious medical conditions. Our vision is to lead the way to a healthier world, and we believe scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything we do, we have charted new paths to life-transforming treatments reflecting ongoing investments in R&D and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.
340 articles about Sunovion Pharmaceuticals Inc.
-
The Day In Review: Biotech Rides Sepracor, Inc. Higher
1/31/2006
-
Sepracor, Inc. Announces Fourth Quarter And Full Year 2005 Results
1/31/2006
-
Sepracor, Inc. Buys ACADIA Pharmaceuticals, Inc. Shares In Partnership
1/17/2006
-
Sepracor, Inc. Receives Notice Of Second Abbreviated New Drug Application Submission For Levalbuterol Hydrochloride Inhalation Solution
1/12/2006
-
Sepracor, Inc. Sets Conference Call And Webcast For Fourth Quarter And Full-Year 2005 Operating Results
1/11/2006
-
Sepracor, Inc. Release: New Medication Helps Relieve Symptoms Associated With Asthma And Copd
12/13/2005
-
Sepracor, Inc. Release: LUNESTA(TM) Data Presented At American College Of Rheumatology Annual Scientific Meeting; Pilot Study Shows Improvement For Insomnia Patients With Co-Existing Rheumatoid Arthritis
11/15/2005
-
Sepracor, Inc. Intends To Reacquire Shares Of Its Common Stock In Call Spread Option Settlements
11/8/2005
-
Sepracor, Inc. Announces Third Quarter 2005 Operating Results
10/25/2005
-
New Drugs To Watch: The Graduates
8/12/2005
-
Ten Drugs To Watch
2/24/2005
-
Biotech/Pharma Earnings Today
1/27/2005
-
CMP Healthcare Media Delivers Inaugural Issue Of Applied Neurology
1/17/2005
-
The Day In Review: Big Deals Push Biotech Higher
12/16/2004
-
Surviving Biotech's Downturns
8/18/2004
-
Paul Royalty Acquires Estorra U.S. Royalty Rights From Aventis For Up to $115 Million
8/10/2004
-
A Look Back At June In Biotech
7/12/2004
-
Rival Pills May Cause Sleepless Nights At Sanofi
3/2/2004
-
Henry Ford Health System Release: New Study Shows Treatment With Xopenex Resulted In Improved Lung Function In Adults With Acute Asthma Attacks
1/26/2004
-
Bedside Biotechs
11/3/2003